Christopher Yamamoto - Bioventus Sr Strategy

Bioventus Management Efficiency

The company has Return on Asset of 0.0248 % which means that on every $100 spent on assets, it made $0.0248 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2476) %, meaning that it generated no profit with money invested by stockholders. Bioventus' management efficiency ratios could be used to measure how well Bioventus manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.46 in 2024. Return On Capital Employed is likely to gain to -0.12 in 2024. At this time, Bioventus' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 3.3 M in 2024, whereas Total Current Assets are likely to drop slightly above 212 M in 2024.

Similar Executives

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the bodys natural healing process in the United States and internationally. The company was founded in 2011 and is headquartered in Durham, North Carolina. Bioventus Inc operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 1160 people. Bioventus (BVS) is traded on NASDAQ Exchange in USA. It is located in 4721 Emperor Boulevard, Durham, NC, United States, 27703 and employs 1,030 people. Bioventus is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Bioventus Leadership Team

Bioventus Stock Performance Indicators

Additional Tools for Bioventus Stock Analysis